Alcon Inc. (ALC) vs Novartis AG (NVS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ALC | NVS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Drug Manufacturers - General |
| Size band | LARGE | MEGA |
| Listing | NYSE | NYSE |
| Country | Switzerland | Switzerland |
| Theme | vision-and-ophthalmology | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $69.99 | $153.81 |
| Return · 1 week | +5.84% | +2.40% |
| Return · 1 month | +7.25% | +4.72% |
| Return · 3 months | +1.27% | −3.78% |
| Return · year to date | −9.37% | +14.40% |
| Return · 1 year | −7.58% | +22.73% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −20.14% | −9.77% |
| 52-week high | $87.64 | $170.46 |
| 52-week low | $61.84 | $121.57 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $33.83B | $292.35B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $108.71M | $264.76M |
| Employees | 25,000 | 75,267 |
| Valuation | ||
| Price to earnings · trailing | 48.57× | 22.75× |
| Price to earnings · forward | 16.17× | 15.37× |
| Price to sales | 2.85× | 5.05× |
| Price to book | 1.44× | 6.89× |
| Enterprise value to EBITDA | 14.27× | 14.20× |
| Enterprise value to revenue | 3.16× | 5.79× |
| PEG ratio | 1.12 | 3.53 |
| Earnings per share · trailing | 1.32 | 6.62 |
| Profitability | ||
| Gross margin | 56.85% | 74.74% |
| Operating margin | 14.63% | 34.62% |
| Profit margin | 5.92% | 22.50% |
| Return on equity | 2.94% | 30.35% |
| Return on assets | 2.80% | 10.25% |
| Growth | ||
| Revenue growth | +8.70% | +0.80% |
| Earnings growth | — | −17.00% |
| Balance sheet and payout | ||
| Debt / equity (%) | 24.54 | 116.85 |
| Current ratio | 2.09 | 0.86 |
| Dividend yield | 0.57% | 3.15% |
| Payout ratio | 26.56% | 71.60% |
| Trend and volatility | ||
| RSI · 14 | 64.42 | 61.14 |
| ADX · 14 | 28.82 | 18.61 |
| 50-day average | $67.87 | $148.17 |
| 200-day average | $72.14 | $151.49 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 1.97% | 1.93% |
The full ALC analysis
Everything this table leaves out for Alcon Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ALC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ALC analysisThe full NVS analysis
Everything this table leaves out for Novartis AG: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NVS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NVS analysis